Genetic assay is predictive of prognosis for kidney cancer
the ONA take:
Researchers in Singapore have developed a test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC). ccRCC is the most common type of kidney cancer.
Treatment options include surgery to remove the tumor and tyrosine kinase inhibitor (TKI) therapy. Prognosis for patients, however, is difficult to predict because outcomes vary. This new test identifies genetic markers of different ccRCC subtypes.
In developing this test, the researchers identified eight genes whose expression levels differed between two subtypes of the disease.
Furthermore, the expression profiles of the eight genes proved to reliably predict good or poor prognosis in patients with ccRCC who received TKI therapy as well as underwent surgery.
The researchers report that the assay could be used as a tool to improve surveillance strategies for patients with ccRCC, but clinical trials are needed to determine the assay’s value in relation to various therapies.
A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|